Article Text

Download PDFPDF
Towards optimal pancreatic cyst fluid management: the need for standardisation
  1. Giacomo Puppa,
  2. Yann Christinat,
  3. Thomas Alexander McKee
  1. Department of Clinical Pathology, Geneva University Hospital, Geneva, Switzerland
  1. Correspondence to Dr Giacomo Puppa, Department of Clinical Pathology, Geneva University Hospital, Geneva 1211, Switzerland; giacomo.puppa{at}

Statistics from

We read with interest the paper by Singhi et al.1 The authors prospectively assessed using targeted next-generation sequencing (NGS) 626 pancreatic cyst fluid (PCF) samples from 595 patients. They found that compared with Sanger sequencing, cytology and CEA, preoperative NGS for KRAS/GNAS mutations is highly sensitive for intraductal papillary mucinous neoplasms (IPMNs) and specific for mucinous pancreatic cysts (PCs).

Moreover, alterations in TP53/PIK3/PTEN are significantly associated with advanced neoplasia facilitating decision-making for the management of these …

View Full Text


  • Contributors GP and YC wrote the letter. TAMK edited the text for important intellectual content.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.